搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按相关度排序
按时间排序
Zacks.com on MSN
6 天
Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why
The pipeline setbacks related to SAGE's neurology candidate, SAGE-324, being developed for essential tremor, weigh heavily on ...
6 天
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...
5 天
Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide
Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after ...
3 天
Sage Therapeutics price target lowered to $8 from $9 at Wedbush
Wedbush lowered the firm’s price target on Sage Therapeutics to $8 from $9 and keeps a Neutral rating on the shares. The firm ...
bovnews
1 天
SAGE Therapeutics Inc (SAGE) Stock: Greater Than Its Current Valuation?
On Friday, SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $6.59 which represents a slight increase of $0.22 or 3.45% from the prior close of $6.37. The stock opened at $6.33 ...
4 天
SAGE Therapeutics: Hold Rating Amid Clinical Setbacks and Narrowed Success Prospects
SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas ...
4 天
SAGE Therapeutics (SAGE) Gets a Hold from TD Cowen
TD Cowen analyst Ritu Baral maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of ...
4 天
Sage Therapeutics股票目标价因试验失败而下调
周三,贝尔德(Baird)调整了对Sage Therapeutics (NASDAQ:SAGE)股票的展望,将目标价从之前的13.00美元下调至9.00美元,同时维持对该股的中性评级。这一决定是在dalzanemdor用于阿尔茨海默病的2期LIGHTWAVE试验失败的公告之后做出的。试验的结果使投资者的全部注意力转向了该公司的另一个前景,即Zurzuvae。 LIGHTWAVE试验是Sage Th ...
5 天
on MSN
Sage Therapeutics stock drops after disappointing Alzheimer's trial results
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results ...
5 天
on MSN
Sage Therapeutics’ stock slides after biotech says it will cease development of Alzheimer ...
Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild ...
5 天
Sage Therapeutics目标价因研究失望而下调至9美元
周二,Oppenheimer调整了对Sage Therapeutics (NASDAQ:SAGE)的展望,将目标价从之前的10美元下调至9美元,同时维持对该股的"表现"评级。这一调整是在Sage宣布其药物dalzanemdor未能在评估阿尔茨海默病相关轻度认知障碍(AD-MCI)患者治疗的2期LIGHTWAVE研究中达到主要目标之后做出的。 LIGHTWAVE研究的结果被视为一个挫折,尽管在该药物 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈